Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA, USA.
Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA.
Nat Genet. 2022 Dec;54(12):1803-1815. doi: 10.1038/s41588-022-01233-6. Epub 2022 Dec 6.
The discovery of genetic loci associated with complex diseases has outpaced the elucidation of mechanisms of disease pathogenesis. Here we conducted a genome-wide association study (GWAS) for coronary artery disease (CAD) comprising 181,522 cases among 1,165,690 participants of predominantly European ancestry. We detected 241 associations, including 30 new loci. Cross-ancestry meta-analysis with a Japanese GWAS yielded 38 additional new loci. We prioritized likely causal variants using functionally informed fine-mapping, yielding 42 associations with less than five variants in the 95% credible set. Similarity-based clustering suggested roles for early developmental processes, cell cycle signaling and vascular cell migration and proliferation in the pathogenesis of CAD. We prioritized 220 candidate causal genes, combining eight complementary approaches, including 123 supported by three or more approaches. Using CRISPR-Cas9, we experimentally validated the effect of an enhancer in MYO9B, which appears to mediate CAD risk by regulating vascular cell motility. Our analysis identifies and systematically characterizes >250 risk loci for CAD to inform experimental interrogation of putative causal mechanisms for CAD.
与复杂疾病相关的遗传基因座的发现速度超过了对疾病发病机制的阐明。在这里,我们进行了一项针对冠状动脉疾病(CAD)的全基因组关联研究(GWAS),该研究包含了 1165690 名主要为欧洲血统的参与者中的 181522 例病例。我们检测到了 241 个关联,包括 30 个新的基因座。与日本 GWAS 的跨种族荟萃分析产生了 38 个额外的新基因座。我们使用功能信息精细映射来优先考虑可能的因果变异,结果有 42 个关联在 95%可信区间内的变异少于五个。基于相似性的聚类表明,早期发育过程、细胞周期信号和血管细胞迁移和增殖在 CAD 的发病机制中起作用。我们结合了八种互补方法,对 220 个候选因果基因进行了优先级排序,其中包括 123 个得到了三种或更多方法支持的基因。我们使用 CRISPR-Cas9 实验验证了 MYO9B 中增强子的作用,该增强子似乎通过调节血管细胞运动来介导 CAD 风险。我们的分析确定并系统地描述了 >250 个 CAD 风险基因座,为实验研究 CAD 的潜在因果机制提供了信息。